Medexus Pharmaceuticals Inc. (MDP:TSX; MEDXF:OTCQX) clarified details of the cash payment it is obligated to make to its German pharma partner Medac GmbH if the U.S. Food and Drug Administration (FDA) approves the former's drug, treosulfan, for bone marrow conditioning, reported Dr. Douglas Loe, Leede Financial Inc. managing director and analyst, in a Dec. 2 research note. The FDA's decision is expected in January 2025.
"A favorable FDA review is imminently justified in our view and, if it transpires, would mitigate risk to our fiscal years 2026 to 2028 (FY26–28) revenue and EBITDA projections," Loe wrote, based on Leede Financial's review of treosulfan's published clinical history and despite the drug's U.S. regulatory history being "clearly mixed."
200% Return Potential
Leede reiterated its CA$8.25 per share target price on Medexus, trading at the time of the report around CA$2.75 per share, noted Loe. The difference between these prices implies a possible 200% return for investors.
The Ontario, Canada-based biopharma remains a Speculative Buy.
"Near-term shareholder value creation is more event-driven at present and heavily focused on the aforementioned U.S. FDA treosulfan regulatory review," Loe commented.
Potential Payment Amounts
The amount of the payment to Medac, which an FDA approval of treosulfan will trigger, will be between US$15 million (US$15M) and US$45M, depending on the drug labeling the agency requires and/or allows. In comparison, the biopharma had US$6.9M in cash as of Sept. 30, 2025, the end of its Q2 FY25.
On the lower end of the range, Medexus must pay US$15M if the FDA does not require any comparative characteristics of treosulfan on the product label. The payment will be US$20M if the FDA allows treosulfan to be deemed noninferior, but not clinically superior, to alternative bone marrow conditioning drugs. Loe noted these specifications likely pertain to the competing drug, busulfan.
The payment to Medac jumps to US$45M if the FDA allows Medexus to claim treosulfan is clinically superior to alternative drugs. According to Loe, Treosulfan warrants this claim based on its clinical data, and Leede Financial would like to see this outcome even though it would increase near-term financial risk to Medexus.
"We do not, however, expect the U.S. FDA to be that daring on label claims it will initially endorse for treosulfan, at least not when considering the drug's mixed regulatory history with the agency," Loe wrote.
Payment Timeline Provided
Medexus provided a payment schedule only for the lowest potential amount owed, US$15M, reported Loe. The firm indicated it would remit the total in three tranches in consecutive quarters, the last one by calendar year-end 2025.
Specifically, the life sciences firm would pay Medac US$2.5M by the end of Q1 FY26 (June 30, 2025), US$5M at the end of Q2 FY26 (Sept. 30, 2025) and US$7.5M at the end of Q3 FY26 (Dec. 31, 2025).
Medexus may defer any of these payments at its discretion, by three months for the first one, four months for the second and one month for the third, but on any delayed payments it must add 9% in annualized interest. Despite having the option, Medexus likely will not delay payments, Loe purported.
Peak Sales of US$100M
Medexus management reiterated its projection that treosulfan could achieve peak U.S. sales of US$100M within five years of a commercial launch there, Loe reported. Leede Financial believes this is aggressive, based on its pricing assumptions, the expected pace of adoption in acute myeloid leukemia and myelodysplastic syndrome allogeneic hematopoietic stem cell transplantation procedures and the understanding treosulfan only will target these two indications during the forecast period.
Yet, Leede Financial still models that peak U.S. treosulfan sales of US$83M–96M are achievable by FY33–FY34 but believes attaining this might require higher pricing and expanded indications in transplantation medicine for the drug, wrote Loe. The model assumes that treosulfan could be priced at about US$8,500–9,500 per procedure, at a premium to alternative bone marrow conditioning agents, like busulfan, now at generic pricing.
"Over time, it is conceivable that treosulfan could be deployed as a bone marrow conditioning agent in transplantation markets where only autologous stem cell transplantation procedures are conducted, including in multiple myeloma and in other leukemia forms," added Loe.
| Want to be the first to know about interesting Biotechnology / Pharmaceuticals investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter. | Subscribe |
Important Disclosures:
- Doresa Banning wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor.
- This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
- This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
For additional disclosures, please click here.
Disclosures for Leede Financial Inc., Medexus Pharmaceuticals Inc., December 2, 2024
Important Information and Legal Disclaimers Leede Financial Inc. (Leede) is a member of the Canadian Investment Regulatory Organization (CIRO) and a member of the Canadian Investor Protection Fund (CIPF). This document is not an offer to buy or sell or a solicitation of an offer to buy or sell any security or instrument or to participate in any particular investing strategy. Data from various sources were used in the preparation of these documents; the information is believed but in no way warranted to be reliable, accurate and appropriate. All information is as of the date of publication and is subject to change without notice. Any opinions or recommendations expressed herein do not necessarily reflect those of Leede. Leede cannot accept any trading instructions via e-mail as the timely receipt of e-mail messages, or their integrity over the Internet, cannot be guaranteed. Dividend yields change as stock prices change, and companies may change or cancel dividend payments in the future. All securities involve varying amounts of risk, and their values will fluctuate, and the fluctuation of foreign currency exchange rates will also impact your investment returns if measured in Canadian Dollars. Past performance does not guarantee future returns, investments may increase or decrease in value, and you may lose money. Leede employees may buy and sell shares of the companies that are recommended for their own accounts and for the accounts of other clients. Disclosure codes are used in accordance with Policy 3600 of CIRO.
Dissemination All final research reports are disseminated to existing and potential institutional clients of Leede Financial Inc. (Leede) in electronic form to intended recipients thorough e-mail and third-party aggregators. Research reports are posted to the Leede website and are accessible to customers who are entitled to the firm’s research. Reproduction of this report in whole or in part without permission is prohibited. Research Analyst Certification The Research Analyst(s) who prepare this report certify that their respective report accurately reflects his/her personal opinion and that no part of his/her compensation was, is, or will be directly or indirectly related to the specific recommendations or views as to the securities or companies. Leede Financial Inc. (Leede) compensates its research analysts from a variety of sources and research analysts may or may not receive compensation based upon Leede investment banking revenue. Canadian Disclosures This research has been approved by Leede Financial Inc. (Leede), which accepts sole responsibility for this research and its dissemination in Canada. Leede is registered and regulated by the Canadian Investment Regulatory Organization (CIRO) and is a member of the Canadian Investor Protection Fund (CIPF). Canadian clients wishing to effect transactions in any designated investment discussed should do so through a Leede Registered Representative. U.S. Disclosures This research report was prepared by Leede Financial Inc. (Leede). Leede is registered and regulated by the Canadian Investment Regulatory Organization (CIRO) and is a member of the Canadian Investor Protection Fund (CIPF). This report does not constitute an offer to sell or the solicitation of an offer to buy any of the securities discussed herein. Leede is not registered as a broker-dealer in the United States and is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. Any resulting transactions should be effected through a U.S. broker-dealer.
